Literature DB >> 10696914

Copolymer 1 inhibits experimental autoimmune uveoretinitis.

M Zhang1, C C Chan, B Vistica, V Hung, B Wiggert, I Gery.   

Abstract

Copolymer 1 (Cop 1) inhibits experimental allergic encephalomyelitis induced by a variety of myelin proteins, but has been found ineffective so far in inhibiting other experimental autoimmune diseases such as diabetes or arthritis. Here, we report for the first time that Cop I inhibits the development of experimental autoimmune uveoretinitis, induced in mice by interphotoreceptor retinoid-binding protein (IRBP). Pooled data of three experiments showed that treatment with Cop 1, at 0.5 mg/mouse, reduced the disease severity by 53% ( p = 0.0002). Cop 1 treatment also inhibited the proliferation and the production of cytokines by lymph node cells in response to IRBP and moderately reduced the antibody response to this antigen. The possible mechanisms of EAU inhibition by Cop 1 are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10696914     DOI: 10.1016/s0165-5728(99)00239-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

Review 1.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

2.  Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.

Authors:  Rakel Carpintero; Karim J Brandt; Lyssia Gruaz; Nicolas Molnarfi; Patrice H Lalive; Danielle Burger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

Review 3.  The Evolving Mechanisms of Action of Glatiramer Acetate.

Authors:  Thomas Prod'homme; Scott S Zamvil
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 4.  Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

Authors:  Patrice H Lalive; Oliver Neuhaus; Mahdia Benkhoucha; Danielle Burger; Reinhard Hohlfeld; Scott S Zamvil; Martin S Weber
Journal:  CNS Drugs       Date:  2011-05       Impact factor: 5.749

Review 5.  Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Authors:  Martin S Weber; Reinhard Hohlfeld; Scott S Zamvil
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

6.  Inhibition of experimental autoimmune uveitis by amino acid copolymers.

Authors:  Hongen Yin; Barbara P Vistica; Chi-Chao Chan; Jack L Strominger; Igal Gery
Journal:  J Neuroimmunol       Date:  2009-09-11       Impact factor: 3.478

7.  Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

Authors:  Danielle Burger; Nicolas Molnarfi; Martin S Weber; Karim J Brandt; Mahdia Benkhoucha; Lyssia Gruaz; Michel Chofflon; Scott S Zamvil; Patrice H Lalive
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

Review 8.  The double-edged sword of autoimmunity: lessons from multiple sclerosis.

Authors:  Anne Lise K Hestvik
Journal:  Toxins (Basel)       Date:  2010-04-22       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.